Nanoparticles Loaded with a New Thiourea Derivative: Development and Evaluation Against .

Background: Leishmaniasis is a neglected tropical disease caused by protozoa of the genus . Current treatments are restricted to a small number of drugs that display both severe side effects and a potential for parasites to develop resistance. A new -(3,4-methylenedioxyphenyl)-'- (2-phenethyl) thiourea compound (thiourea 1) has shown promising activity against with an IC of 54.

Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis.

The oral efficacy and safety of a leishmanicidal nitrochalcone (CH8) were studied in BALB/c mouse infections with and Although 10-fold-higher doses of CH8 were needed to produce the same antiparasitic effect as that seen with the reference drug miltefosine, the latter was nephrotoxic, whereas CH8 restored disease toxicity markers to normal. This study shows the therapeutic potential of an orally active and hepato-/nephroprotective chalcone against cutaneous and visceral leishmaniases.